On September 20, 2021 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported an upcoming presentation at the 3rd Annual RAS Targeted Drug Development Summit that will feature data from a Phase 1/2a investigator-initiated study evaluating rigosertib in combination with nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC) (Press release, Onconova, SEP 20, 2021, View Source [SID1234588014]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the presentation are shown below.
Track:
Advancing Translation & Clinical Development
Session Title:
Evaluating the Landscape of Clinical Trials – Successes, Insights & Learnings
Presentation Date:
September 22, 2021
Presentation Time:
11:30 a.m. ET
Presentation Title:
Phase 1 Clinical Trial Updates for Oral Rigosertib & PD-1 Inhibitor in KRAS-mutated NSCLC
Presenter: Rajwanth Veluswamy, MD, MSCR, Assistant Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Those interested in registering for the summit can do so here.